A Phase III Randomized Trial of Gemcitabine–Oxaliplatin versus Carboplatin–Paclitaxel as First-Line Therapy in Patients with Advanced Non-small Cell Lung Cancer Charles H. Weissman, MD, Craig H. Reynolds, MD, Marcus A. Neubauer, MD, Sharon Pritchard, RN, Svetlana Kobina, MD, PhD, Lina Asmar, PhD Journal of Thoracic Oncology Volume 6, Issue 2, Pages 358-364 (February 2011) DOI: 10.1097/JTO.0b013e3181ffe8ef Copyright © 2011 International Association for the Study of Lung Cancer Terms and Conditions
FIGURE 1 Patient disposition. Journal of Thoracic Oncology 2011 6, 358-364DOI: (10.1097/JTO.0b013e3181ffe8ef) Copyright © 2011 International Association for the Study of Lung Cancer Terms and Conditions
FIGURE 2 A, Kaplan-Meier estimates of progression-free survival* (intent-to-treat population). B, Kaplan-Meier estimates of overall survival (intent-to-treat population). GEMOX, gemcitabine plus oxaliplatin; PCb, paclitaxel plus carboplatin. Journal of Thoracic Oncology 2011 6, 358-364DOI: (10.1097/JTO.0b013e3181ffe8ef) Copyright © 2011 International Association for the Study of Lung Cancer Terms and Conditions
FIGURE 3 A, Kaplan-Meier estimated survival for patients aged 70 years or older. B, Kaplan-Meier estimated survival for patients with adenocarcinoma. GEMOX, gemcitabine plus oxaliplatin; PCb, paclitaxel plus carboplatin. Journal of Thoracic Oncology 2011 6, 358-364DOI: (10.1097/JTO.0b013e3181ffe8ef) Copyright © 2011 International Association for the Study of Lung Cancer Terms and Conditions